Commercialization: Page 31
-
PharmaVoice Team/PharmaVoice
Behind the Brand — Lessons Learned
According to the global branding and design firm Landor, the process of managing brands — or brand governance — has changed dramatically in recent years. The command-and-control model is obsolete in today’s more agile and dynamic marketplace. In this new world, multiple communities, including em...
By Robin Robinson • May 1, 2017 -
PharmaVoice Team/PharmaVoice
Hepatitis Market Update
In just a few short years, hepatitis infections could go from a serious disease to one that will be rare. Pharmaceutical companies have done much to address hepatitis in recent years. Today, hepatitis B is preventable with vaccination, and recent advances in treatment have made hepatitis C curabl...
By Denise Myshko • May 1, 2017 -
PharmaVoice Team/PharmaVoice
SHOWCASE FEATURE: mHealth: Seeing the Potential in mHealth
Mobile is ubiquitous. Consumers use mobile apps to search for information about everything from retail products to news and sports and, increasingly, to monitor their health. A report from comScore found that mobile now represents 65% of digital media time, and that desktop computers are becoming...
By PharmaVoice Team • May 1, 2017 -
PharmaVoice Team/PharmaVoice
The Impact of mHealth on Real-World Data Collection
Advancements in technology over the past five years have led to increased interest around the topic of mHealth — the monitoring and delivery of healthcare through mobile devices. Approximately 93% of us now own a mobile phone and, with an increased desire from the pharmaceutical industry to use e...
By PharmaVoice Team • May 1, 2017 -
PharmaVoice Team/PharmaVoice
A Patient-Centric Approach to mHealth
The possibilities for mHealth solutions are vast and expanding, so how can pharmaceutical brands know how to enter the space, or even if they should? Consider Your Patients First Patients are actively searching for ways to live healthier lives, prevent illness, manage chronic conditions, and keep...
By Dara Liguori • May 1, 2017 -
PharmaVoice Team/PharmaVoice
mHealth Evolution
Ten years after the launch of Apple’s iPhone in 2007, mobile healthcare (mHealth) technology and consumer adoption continues to advance. mHealth is a general term for the use of mobile wireless technology for medical care, health, and fitness. As the global population moves from being digitally n...
By Brandie Linfante • May 1, 2017 -
PharmaVoice Team/PharmaVoice
Speak Out
Welcome to the Jungle: The Dilemma of the Healthcare Challenger Brand Marketing a pharmaceutical product or medical device to a healthcare professional audience has changed radically, even for market leaders and establishment brands. But for challenger brands—the brands with something to prove, o...
By Frank X. Powers • May 1, 2017 -
PharmaVoice Team/PharmaVoice
Letter from the Editor
Working in concert The act of collaborating with competitors, no less with companies and organizations outside of traditional “pharma," was a concept that might have been considered heresy — until recently. Sure, there were agreements with academic centers or cross-licensing deals to capitalize o...
By Taren Grom • April 1, 2017 -
PharmaVoice Team/PharmaVoice
Upfront
Sunovion Teams up with Demi Lovato for Mental Health Documentary Sunovion Pharmaceuticals, five leading mental health advocacy organizations, and multi-platinum, Grammy-nominated singer, songwriter, and mental health advocate Demi Lovato have released Beyond Silence, a documentary film created by...
By PharmaVoice Team • April 1, 2017 -
PharmaVoice Team/PharmaVoice
Last Word
Defining Value for Payers Kelly Wilder, Executive VP, Managing Partner, Precision for Value, discusses why the value propositions pharmaceutical companies use should change depending on the payer audience. PV: How has the payer landscape changed? WILDER: The changes in the payer space over the la...
By Kelly Wilder • April 1, 2017 -
PharmaVoice Team/PharmaVoice
A New Era of Collaboration
This month’s special issue examines the new era of collaboration from R&D to commercialization and the role various players have in shaping the future of the life-sciences industry. According to a recent KPMG report, the majority of the 400 U.S. chief executives surveyed say the next three ye...
By Taren Grom • April 1, 2017 -
PharmaVoice Team/PharmaVoice
Collaborating A Necessary Component of Success
In 2009, PwC predicted that the pharma business model would evolve to a more patient-centric and collaborative approach by the year 2020. Three years from that deadline, there is plenty of evidence that the industry has started to collaborate both inside and outside of the “traditional" industry ...
By Robin Robinson • April 1, 2017 -
PharmaVoice Team/PharmaVoice
The Influence of Nontraditional Players
Nontraditional players have recognized the tremendous opportunity that lies in the healthcare space, and are innovating with or without pharma partners to solve many of the healthcare issues that patients are dealing with. Companies such as Apple, Google, General Electric, Samsung, Microsoft, and...
By Robin Robinson • April 1, 2017 -
PharmaVoice Team/PharmaVoice
R&D Partnerships
The pressure on the pharmaceutical industry to bring innovative medications to the market — as well as address issues related to access, cost, and value — is requiring new ways of doing research and development. Couple this with how quickly science is advancing and the volume of data that is bein...
By Denise Myshko • April 1, 2017 -
PharmaVoice Team/PharmaVoice
Collaboration within the Commercialization Process
According to a recent Strategy& report about how to overcome industry obstacles with a cross-functional strategy, beyond the many external challenges that pharma is facing that require collaboration with outside partners, pharma also must address divides within its internal commercial culture...
By Robin Robinson • April 1, 2017 -
PharmaVoice Team/PharmaVoice
Collaborating For Value
Changes across the healthcare industry are putting pressures on pharmaceutical companies to provide value to customers and stakeholders. Analysts and executives say the industry will have to watch the intertwining of provider, payer, digital, and pharma value chains closely as we enter an era tha...
By Denise Myshko • April 1, 2017 -
PharmaVoice Team/PharmaVoice
SHOWCASE FEATURE: Global Markets: Preparing for the Next Big Markets
According to PwC, the global pharmaceutical market will be worth almost $1.6 trillion by 2020. But with growth in mature markets slowing, a lot of the growth will come from emerging economies. In fact, according to McKinsey, emerging markets are expected to account for $190 billion in sales growt...
By PharmaVoice Team • April 1, 2017 -
PharmaVoice Team/PharmaVoice
Global Markets
Global markets have long held the promise of a rapid growth opportunity for the pharmaceutical industry, and indeed all forecasts continue to point to emerging markets being an engine of growth in volume and value of use of medicines. A closer look reveals that uptake of innovative medicines will...
By Steve Mather • April 1, 2017 -
PharmaVoice Team/PharmaVoice
Last Word
PhRMA Initiative Aims to Create a Dialogue about the Value of Medicines Robert Zirkelbach, Executive VP, Public Affairs, PhRMA, talks about the association’s new advertising and public affairs campaign. PV: Why did PhRMA launch the GoBoldly campaign? Zirkelbach: For the last couple of years, ther...
By Robert Zirkelbach • March 1, 2017 -
PharmaVoice Team/PharmaVoice
Industry Transformation: Industry Disruption
Most disruptive technology initiatives are taking place in smaller, more agile companies, and in the clinical trial phase of development, but even big companies such as Pfizer and GSK are testing the possibilities of artificial intelligence, blockchain, and especially mobile and other transformat...
By PharmaVoice Team • March 1, 2017 -
PharmaVoice Team/PharmaVoice
Big Data
As the useful applications of big data in the pharmaceutical and healthcare sector become increasingly apparent, 73% of organizations in the industry are set to begin or increase investment in big data within the next five years, according to business intelligence provider GBI Research. The repor...
By Robin Robinson • March 1, 2017 -
PharmaVoice Team/PharmaVoice
Patient Stories
As the industry continues to embrace a more patient-centric business model, patient views have shifted to the forefront of several strategies, including using patient advisory boards for drug development and clinical trial protocols, and patient stories and communities to guide marketing and othe...
By Robin Robinson • March 1, 2017 -
PharmaVoice Team/PharmaVoice
A Nuanced Message: Marketing to the Rare Diseases Community
Check traditional marketing strategies at the door, because when it comes to rare diseases they simply don’t apply. Experts say established methods of directing campaigns toward physicians don’t work because unlike large therapeutic categories, such as cardiovascular or diabetes, the patients and...
By Kim Ribbink • March 1, 2017 -
PharmaVoice Team/PharmaVoice
SHOWCASE FEATURE: Market Research: Getting the Most From the Data in Market Research
The global pharmaceutical market was worth around $300 billion in 2015, according to the World Health Organization, and it is expected to surpass $400 billion by 2018 with a third of that value in the hands of the top 10 companies. But as the age of the blockbuster ends, pharmaceutical companies ...
By PharmaVoice Team • March 1, 2017 -
PharmaVoice Team/PharmaVoice
How Well Do You Really Know Your Patients?
Global Genes reports that therapy adherence in the rare disease space can vary from only 58% to 65%, a troubling statistic for our industry, and most importantly, the patients we serve. Manufacturers must be wondering, how well do we really know our patients and what they need? Many orphan drug m...
By Linda Newberry-Ferguson • March 1, 2017
Previous
